25 July 2025 in Science Advances
In vivo conversion of nonneuronal cells into neurons is a proposed strategy to replace neurons lost to CNS injury or disease. Glia-to-neuron trans-differentiation by viral vector–mediated GFAP mini-promoter–driven NeuroD1 remains hotly debated. Developing inducible, lineage-traceable transgenic mice, we find that astrocyte-to-neuron conversion is restricted to a specific time window within the lesion core of injured spinal cord and brain. Spatiotemporal lineage-mapping combined with single-cell transcriptomics reveals that ectopic NeuroD1 induces astrocyte-to-neuron conversion specifically in lesion cores via transit-amplifying OLIG2 + progenitors during early injury phase, but not in late phases or in nonreactive astrocytes. Neither a loss-of-function NeuroD1 mutant nor stemness-reprogramming factor SOX2 induces astrocyte-to-neuron conversion. However, contrary to previous reports, the neuronal-like cells generated by NeuroD1 lack mature neuroelectrical properties, limiting their functional integration into neural circuits. Together, our findings establish a spatiotemporal framework for NeuroD1-driven glia-to-neuron conversion, revealing a mechanistic shift from direct astrocyte conversion toward transit-amplifying intermediates and highlighting the functional immaturity of NeuroD1-converted neurons.
31 August 2026 in Neuro-Oncology
Background: Diffuse middle glioma (DMG or DIPG) is a fatal pediatric brain tumor. Although chimeric antigen receptor (CAR) T-cell therapy shows promise, clinical outcomes remain inconsistent due to premature exhaustion, underscoring a critical need to improve CAR-T persistence. A major barrier to CAR-T efficacy is antigen-independent tonic signaling, yet the extent to which tonic signaling shapes CAR-T durability and clinical outcomes, particularly in DMG, remains incompletely defined. Methods: Using a clinically investigated B7-H3 MGA271-based CAR as a reference platform, we generated alternative B7-H3 CARs incorporating either a human codon-optimized 376.96 (B7H3.BC) or Hu8H9 scFv antigen-binding domain to systematically assess scFv-dependent effects on tonic signaling and therapeutic efficacy. CAR-T cells were evaluated using integrated in vitro and in vivo functional assays, alongside multi-omics profiling and computational modeling. We further derived a tonic signaling-associated gene signature and evaluated its predictive performance across independent clinical datasets. Results: B7H3.BC CAR-T cells exhibit markedly restrained tonic signaling compared with MGA271- and Hu8H9-based counterparts, accompanied by superior antitumor activity and enhanced persistence across patient-derived DMG cells. Integrated multi-omics and single-cell profiling further identified a tonic signaling-associated gene signature that outperforms conventional T-cell exhaustion signatures in predicting therapeutic efficacy across multiple clinical trials, including DMG and other tumors. Conclusions: Our findings establish that scFv-dependent modulation of tonic signaling critically governs CAR-T persistence and antitumor efficacy in DMG. By linking CAR design to transcriptional and epigenetic programs, our study provides a principle-based and predictive framework to inform rational CAR engineering and improve therapeutic outcomes.